RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Emmaus Life Sciences Stock

Emmaus Life Sciences ROCE 2024

Emmaus Life Sciences ROCE

-0.07

Ticker

EMMA

ISIN

US29137T1016

WKN

A2PNWG

In 2024, Emmaus Life Sciences's return on capital employed (ROCE) was -0.07, a -138.35% increase from the 0.19 ROCE in the previous year.

Emmaus Life Sciences Aktienanalyse

What does Emmaus Life Sciences do?

Emmaus Life Sciences Inc. is an innovative US-American company that develops, produces, and markets medications based on L-Glutamine. The company was founded in 2000 by Dr. Yutaka Niihara, a Japanese researcher who grew up in the USA and received his doctorate from Harvard Medical School. The idea for founding Emmaus Life Sciences arose from the observation of patients with sickle cell anemia, an inherited blood disease. These patients suffer from intense pain attacks caused by the clumping of red blood cells in the body. Dr. Niihara and his colleagues researched the effects of L-Glutamine on these pain attacks and were able to demonstrate that L-Glutamine can significantly reduce the frequency and intensity of the pain attacks. Based on these research results, Emmaus Life Sciences developed the medication "Endari," which was approved by the US-American regulatory authority FDA in 2017. "Endari" is the first medication specifically approved for the treatment of sickle cell anemia. It is intended to reduce the frequency and severity of pain attacks in patients with sickle cell anemia. Since its founding in 2000, Emmaus Life Sciences has expanded significantly. The company now has multiple locations in the USA and employs over 150 employees. Emmaus Life Sciences operates in two business areas: medications and health products. In the medication area, Emmaus Life Sciences focuses on the development of drugs for rare diseases. In addition to "Endari," the company is working on the development of medications for the treatment of mucopolysaccharidosis (MPS) and acid peptidase deficiency (ASM). In the health products area, Emmaus Life Sciences specializes in the production and marketing of dietary supplements. The company has developed a range of products based on L-Glutamine as the active ingredient. These products are intended to support the health of athletes, people with special dietary needs, older adults, and people with certain diseases. Emmaus Life Sciences' products include L-Glutamine powder for daily use, L-Glutamine capsules for athletes and bodybuilders, L-Glutamine for clinical nutrition, and a special L-Glutamine product for people with chronic kidney disease. Emmaus Life Sciences is an innovative company that builds its products on scientifically validated research results. The company specializes in the development of medications and health products that help people improve their health and increase their quality of life. Emmaus Life Sciences ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROCE Details

Unraveling Emmaus Life Sciences's Return on Capital Employed (ROCE)

Emmaus Life Sciences's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing Emmaus Life Sciences's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

Emmaus Life Sciences's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in Emmaus Life Sciences’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about Emmaus Life Sciences stock

What is the ROCE (Return on Capital Employed) of Emmaus Life Sciences this year?

The ROCE of Emmaus Life Sciences is -0.07 undefined this year.

How has the ROCE (Return on Capital Employed) of Emmaus Life Sciences developed compared to the previous year?

The ROCE of Emmaus Life Sciences has increased by -138.35% decreased compared to the previous year.

What does a high ROCE (Return on Capital Employed) mean for investors of Emmaus Life Sciences?

A high Return on Capital Employed (ROCE) indicates that Emmaus Life Sciences has efficient capital utilization and is able to achieve a higher return on its invested capital. This can be appealing to investors.

What does a low ROCE (Return on Capital Employed) mean for investors of Emmaus Life Sciences?

A low ROCE (Return on Capital Employed) can indicate that Emmaus Life Sciences has an inefficient utilization of its capital and may have difficulty in achieving a satisfactory return on its invested capital. This can be uncertain or unattractive for investors.

How does an increase in ROCE from Emmaus Life Sciences impact the company?

An increase in the ROCE of Emmaus Life Sciences can be an indicator of improved company efficiency and show that it is achieving higher profits in relation to its investments.

How does a reduction in the ROCE of Emmaus Life Sciences affect the company?

A decrease in ROCE of Emmaus Life Sciences can be an indicator of deteriorated efficiency of the company, indicating that it is generating lower profits in relation to its investments.

What are some factors that can influence the ROCE of Emmaus Life Sciences?

Some factors that can affect Emmaus Life Sciences's ROCE include efficiency in managing assets, profitability of investments, cost efficiency, and market conditions.

Why is the ROCE of Emmaus Life Sciences so important for investors?

The ROCE of Emmaus Life Sciences is important for investors as it is an indicator of the company's efficiency and shows how successful the company is in relation to its investments. A high ROCE can indicate strong financial performance of the company.

What strategic measures can Emmaus Life Sciences take to improve the ROCE?

To improve the ROCE, Emmaus Life Sciences can take measures such as increasing efficiency in asset management, optimizing investments, cost savings, and exploring new revenue sources. It is important for the company to conduct a thorough review of its operations to determine the best strategic actions to improve the ROCE.

How much dividend does Emmaus Life Sciences pay?

Over the past 12 months, Emmaus Life Sciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Emmaus Life Sciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Emmaus Life Sciences?

The current dividend yield of Emmaus Life Sciences is .

When does Emmaus Life Sciences pay dividends?

Emmaus Life Sciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Emmaus Life Sciences?

Emmaus Life Sciences paid dividends every year for the past 0 years.

What is the dividend of Emmaus Life Sciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Emmaus Life Sciences located?

Emmaus Life Sciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Emmaus Life Sciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Emmaus Life Sciences from 9/10/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/10/2024.

When did Emmaus Life Sciences pay the last dividend?

The last dividend was paid out on 9/10/2024.

What was the dividend of Emmaus Life Sciences in the year 2023?

In the year 2023, Emmaus Life Sciences distributed 0 USD as dividends.

In which currency does Emmaus Life Sciences pay out the dividend?

The dividends of Emmaus Life Sciences are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Emmaus Life Sciences

Our stock analysis for Emmaus Life Sciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Emmaus Life Sciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.